ITRM960790A0 - Uso di sostanze che attivano il recettore del cntf ( fattore neurotro fico ciliare) per la preparazione di farmaci per la terapia della - Google Patents

Uso di sostanze che attivano il recettore del cntf ( fattore neurotro fico ciliare) per la preparazione di farmaci per la terapia della

Info

Publication number
ITRM960790A0
ITRM960790A0 IT96RM000790A ITRM960790A ITRM960790A0 IT RM960790 A0 ITRM960790 A0 IT RM960790A0 IT 96RM000790 A IT96RM000790 A IT 96RM000790A IT RM960790 A ITRM960790 A IT RM960790A IT RM960790 A0 ITRM960790 A0 IT RM960790A0
Authority
IT
Italy
Prior art keywords
ciliar
drugs
therapy
activate
substances
Prior art date
Application number
IT96RM000790A
Other languages
English (en)
Inventor
Ralph Laufer
Isabelle Glouguen
Patrizia Costa
Marco Annalise Di
Anna Demartis
Domenico Lazzaro
Giacomo Paonessa
Gennaro Ciliberto
Riccardo Cortese
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of ITRM960790A0 publication Critical patent/ITRM960790A0/it
Priority to IT96RM000790A priority Critical patent/IT1288388B1/it
Priority to AT97946043T priority patent/ATE228003T1/de
Priority to DK97946043T priority patent/DK0946189T3/da
Priority to DE69717308T priority patent/DE69717308T2/de
Priority to CN201010282598XA priority patent/CN102145163B/zh
Priority to PCT/IT1997/000283 priority patent/WO1998022128A1/en
Priority to IL12996897A priority patent/IL129968A0/xx
Priority to PT97946043T priority patent/PT946189E/pt
Priority to CN2009102210662A priority patent/CN101703761B/zh
Priority to ES97946043T priority patent/ES2187830T3/es
Priority to EP97946043A priority patent/EP0946189B1/en
Priority to JP52343398A priority patent/JP4067127B2/ja
Priority to CA002271781A priority patent/CA2271781C/en
Priority to AU51344/98A priority patent/AU727174B2/en
Priority to US09/308,368 priority patent/US6565869B1/en
Publication of ITRM960790A1 publication Critical patent/ITRM960790A1/it
Application granted granted Critical
Publication of IT1288388B1 publication Critical patent/IT1288388B1/it
Priority to US10/356,191 priority patent/US6960558B2/en
Priority to IL12996805A priority patent/IL129968A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT96RM000790A 1996-11-19 1996-11-19 Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia IT1288388B1 (it)

Priority Applications (17)

Application Number Priority Date Filing Date Title
IT96RM000790A IT1288388B1 (it) 1996-11-19 1996-11-19 Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
CN2009102210662A CN101703761B (zh) 1996-11-19 1997-11-18 Cntf(睫状神经营养因子)受体激活物在治疗肥胖症上的用途
EP97946043A EP0946189B1 (en) 1996-11-19 1997-11-18 Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity
DE69717308T DE69717308T2 (de) 1996-11-19 1997-11-18 Verwendung von cntf (ciliary neurotrophic factor) rezeptoraktivatoren fur behandlung von fettleibigkeit
CN201010282598XA CN102145163B (zh) 1996-11-19 1997-11-18 Cntf(睫状神经营养因子)受体激活物在治疗肥胖症上的用途
PCT/IT1997/000283 WO1998022128A1 (en) 1996-11-19 1997-11-18 Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity
IL12996897A IL129968A0 (en) 1996-11-19 1997-11-18 use of cntf receptor activators for the treatment of obesity
PT97946043T PT946189E (pt) 1996-11-19 1997-11-18 Utilizacao de activadores do receptor de cntf (factor neurotrofico ciliar) para o tratamento de obesidade
AT97946043T ATE228003T1 (de) 1996-11-19 1997-11-18 Verwendung von cntf (ciliary neurotrophic factor) rezeptoraktivatoren fur behandlung von fettleibigkeit
ES97946043T ES2187830T3 (es) 1996-11-19 1997-11-18 Uso de activadores de receptores del cntf (factor neurotrofico cil iar) para el tratamiento de la obesidad.
DK97946043T DK0946189T3 (da) 1996-11-19 1997-11-18 Anvendelse af aktivatorer af CNTF (ciliær neurotrofisk faktor) receptor til behandling af adipositas
JP52343398A JP4067127B2 (ja) 1996-11-19 1997-11-18 肥満症の処置のためのｃｎｔｆ（毛様体神経成長因子）受容体アクティベーターの使用
CA002271781A CA2271781C (en) 1996-11-19 1997-11-18 Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity
AU51344/98A AU727174B2 (en) 1996-11-19 1997-11-18 Use of CNTF (ciliary neurotrophic factor) receptor activators for the treatment of obesity
US09/308,368 US6565869B1 (en) 1996-11-19 1997-11-18 Use of CNTF (ciliary neurotrophic factor) receptor activators for the treatment of obesity
US10/356,191 US6960558B2 (en) 1996-11-19 2003-01-31 Method of screening for anti-obesity agents using ciliary neutrophic factor receptor
IL12996805A IL129968A (en) 1996-11-19 2005-07-26 Use of cntf receptor activators for the manufacture of a medicament for a medicament for the treatment of obesity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96RM000790A IT1288388B1 (it) 1996-11-19 1996-11-19 Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia

Publications (3)

Publication Number Publication Date
ITRM960790A0 true ITRM960790A0 (it) 1996-11-19
ITRM960790A1 ITRM960790A1 (it) 1998-05-19
IT1288388B1 IT1288388B1 (it) 1998-09-22

Family

ID=11404538

Family Applications (1)

Application Number Title Priority Date Filing Date
IT96RM000790A IT1288388B1 (it) 1996-11-19 1996-11-19 Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia

Country Status (14)

Country Link
US (2) US6565869B1 (it)
EP (1) EP0946189B1 (it)
JP (1) JP4067127B2 (it)
CN (2) CN101703761B (it)
AT (1) ATE228003T1 (it)
AU (1) AU727174B2 (it)
CA (1) CA2271781C (it)
DE (1) DE69717308T2 (it)
DK (1) DK0946189T3 (it)
ES (1) ES2187830T3 (it)
IL (2) IL129968A0 (it)
IT (1) IT1288388B1 (it)
PT (1) PT946189E (it)
WO (1) WO1998022128A1 (it)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
AU718500B2 (en) * 1997-01-23 2000-04-13 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
IT1291114B1 (it) * 1997-03-20 1998-12-29 Angeletti P Ist Richerche Bio Varianti del fattore neurotrofico ciliare (cntf) con migliorata selettivita' al recettore, e metodo per la loro selezione
US6680291B1 (en) 1998-02-27 2004-01-20 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor, method of making and methods of use thereof
SK13082001A3 (sk) 1999-03-29 2002-03-05 The Procter & Gamble Company Cyklický peptidový analóg a jeho výroba
WO2000063357A2 (en) * 1999-04-20 2000-10-26 Beth Israel Deaconess Medical Center Methods and compositions for modulating ciliary neurotrophic factor activity
IL132312A0 (en) * 1999-09-05 2001-03-19 Yeda Res & Dev Use of leptin in inhibition of endothelial cell proliferation
US20030022840A1 (en) * 2000-02-18 2003-01-30 Michiko Kishino Drugs for ameliorating impaired glucose tolerance
US20030036512A1 (en) * 2000-03-06 2003-02-20 Tsutomu Nakagawa Leptin-resistance amerliorating agents
EP1365785A2 (en) * 2000-05-24 2003-12-03 Regeneron Pharmaceuticals, Inc. Use of ciliary neurotrophic factor
AU2001267058A1 (en) * 2000-06-09 2001-12-17 University Of Florida Research Foundation, Inc. Aav vector-based compositions and therapeutic uses thereof
RU2003129069A (ru) * 2001-03-02 2005-04-20 Мерк Патент ГмбХ (DE) Модифицированный цилиарный нейротрофический фактор (cntf) с уменьшенной иммуногенностью
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005014641A2 (en) * 2003-07-09 2005-02-17 Xencor, Inc. Ciliary neurotrophic factor variants
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
WO2006017156A2 (en) * 2004-07-09 2006-02-16 Regeneron Pharmaceuticals, Inc. Methods for identifying a candidate for treatment of obesity
WO2006052608A2 (en) 2004-11-01 2006-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
AU2006277253A1 (en) 2005-08-10 2007-02-15 Msd K.K. Pyridone compound
EP1921065B1 (en) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHIIN DERIVATIVES
EP1953165B1 (en) 2005-11-10 2012-02-01 Msd K.K. Aza-substituted spiro derivative
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
CA2717384A1 (en) 2008-03-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
AU2009277736A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2652662T3 (es) 2011-02-25 2018-02-05 Merck Sharp & Dohme Corp. Novedosos derivados de azabencimidazol cíclicos útiles como agentes antidiabéticos
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2898482A1 (en) 2013-02-22 2014-08-28 Linda L. Brockunier Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104558148B (zh) * 2013-10-17 2018-11-06 北京生物制品研究所有限责任公司 睫状神经营养因子突变体及其修饰型突变体和用途
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
WO2016070419A1 (zh) * 2014-11-07 2016-05-12 陕西麦科奥特科技有限公司 睫状神经营养因子鼻腔给药系统及其制备方法和应用
CN106632650B (zh) * 2015-10-30 2020-11-13 北京生物制品研究所有限责任公司 睫状神经营养因子突变体及其修饰型突变体和应用
CN109952292A (zh) 2016-10-14 2019-06-28 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US11179441B2 (en) 2017-01-06 2021-11-23 The Board Of Trustees Of The Leland Stanford Junior University Ciliary neurotrophic factor receptor ligands and methods of using the same
SG11202005146VA (en) * 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
SI3773713T1 (sl) 2018-04-06 2025-08-29 Regeneron Pharmaceuticals, Inc. Protitelo, agonist leptinskega receptorja, za uporabo pri povečanju kostne mase pri osebi, ki trpi zaradi presnovne disfunkcije ali hipoleptinemije
CN112672732A (zh) * 2018-06-19 2021-04-16 细胞疗法有限责任公司 包含神经营养剂、凋亡信号传导片段抑制剂（FAS）或FAS配体（FASL）抑制剂、肿瘤坏死因子-α（TNF-α）或TNF受体抑制剂、线粒体肽、寡核苷酸、趋化因子抑制剂或半胱氨酸-天冬氨酸蛋白酶的药物递送系统
CA3104468A1 (en) * 2018-06-19 2019-12-26 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a c-type natriuretic peptide compound, an natriuretic peptide receptor-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
WO2020023621A1 (en) * 2018-07-24 2020-01-30 Puneeth Iyengar Improved weight loss therapy
BR112021009589A2 (pt) 2018-11-20 2021-08-17 Tes Pharma S.R.L. inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
EP4076495A4 (en) * 2019-12-18 2023-12-20 Cella Therapeutics, LLC DRUG DELIVERY SYSTEMS INCLUDING NEUROTROPHIC AGENT, APOPTOSIS SIGNALING FRAGMENT (FAS) INHIBITOR OR FAS LIGAND INHIBITOR (FASL), TUMOR NECROSIS FACTOR INHIBITOR? (TNF-A) OR TNF RECEPTOR, MITOCHONDRIAL PEPTIDE, OLIGONUCLEOTIDE, CHEMOKINE INHIBITOR OR ASPARTIC CYSTEINE PROTEASE INHIBITOR

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US4997929A (en) 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US5141856A (en) 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
IE903130A1 (en) 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
CS156891A3 (en) 1990-06-01 1992-04-15 Regeneron Pharma Receptor of a cilary neurotropic factor
CN1061623A (zh) 1990-06-01 1992-06-03 里珍纳龙药品有限公司 睫状神经营养性因子受体
US5426177A (en) 1990-06-01 1995-06-20 Regeneron Pharmaceuticals, Inc. Ciliary neurotrophic factor receptor
AU666327B2 (en) 1991-07-23 1996-02-08 Syntex-Synergen Neuroscience Joint Venture, The Purification of recombinant ciliary neurotrophic factor and C-terminal truncated ciliary neurotrophic factor and methods for treating peripheral nerve damage
US5691313A (en) 1991-07-23 1997-11-25 Amgen Inc. Methods of treating impotency with ciliary neurotrophic factor
US5593857A (en) 1991-08-23 1997-01-14 Scios Inc. Production of homogeneous truncated CNTF
AU2925392A (en) 1991-11-11 1993-06-15 Fidia S.P.A. Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor
US5955290A (en) 1991-12-02 1999-09-21 Regeneron Pharmaceuticals, Inc. Assay systems using the CNTF signal transduction pathway
US5349056A (en) 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US6143714A (en) 1994-10-24 2000-11-07 Regeneron Pharmaceuticals, Inc. Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
IT1284867B1 (it) 1996-07-10 1998-05-22 Angeletti P Ist Richerche Bio Varianti del fattore neurotrofico ciliare umano (hcntf) con uno spettro di azione differente dalla molecola di tipo selvatico
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia

Also Published As

Publication number Publication date
ATE228003T1 (de) 2002-12-15
WO1998022128A1 (en) 1998-05-28
EP0946189A1 (en) 1999-10-06
CN101703761B (zh) 2013-11-20
CN102145163A (zh) 2011-08-10
CA2271781A1 (en) 1998-05-28
US6565869B1 (en) 2003-05-20
US6960558B2 (en) 2005-11-01
DE69717308T2 (de) 2003-07-10
CA2271781C (en) 2002-11-12
AU5134498A (en) 1998-06-10
IL129968A (en) 2005-11-20
CN102145163B (zh) 2013-09-18
CN101703761A (zh) 2010-05-12
PT946189E (pt) 2003-02-28
EP0946189B1 (en) 2002-11-20
AU727174B2 (en) 2000-12-07
DE69717308D1 (de) 2003-01-02
JP4067127B2 (ja) 2008-03-26
JP2000511561A (ja) 2000-09-05
DK0946189T3 (da) 2002-12-16
IT1288388B1 (it) 1998-09-22
IL129968A0 (en) 2000-02-29
ES2187830T3 (es) 2003-06-16
US20030176346A1 (en) 2003-09-18
ITRM960790A1 (it) 1998-05-19

Similar Documents

Publication Publication Date Title
ITRM960790A0 (it) Uso di sostanze che attivano il recettore del cntf ( fattore neurotro fico ciliare) per la preparazione di farmaci per la terapia della
PT101337A (pt) Factor polipeptidico possuindo actividade mitogenica estimulante da divisao de celulas de schwann, sua preparacao e uso
MX9204301A (es) Acilmercaptoalcanoildipeptidos, metodos de preparacion y su uso terapeutico.
IT1192009B (it) Mezzi d ausilio per l uso di servizi igienici
FI961057L (fi) Tabletoitu moniyksikköannostusmuoto I
NO965103L (no) Bicykliske aromatiske forbindelser, anvendelse derav, og farmasöytiske og kosmetiske preparater
ATE210429T1 (de) Therapie mittels gleichförmiger arzneistoffverabreichung
IT1286629B1 (it) Sistema di monitoraggio della radiazione ultravioletta con annesso controllo delle caratteristiche della pelle per la somministrazione di
EP0724387A4 (en) ANGIOTENSIN II RECEPTOR ANTAGONISTS
FI924744A7 (fi) Terapeuttisia aineita
IT1214598B (it) Uso terapeutico della fosfocreatina.
ITPD920145A0 (it) Uso terapeutico della fosforil-serina-n-acil-sfingosina
FI923662A7 (fi) Terapeuttisia aineita
ITMI942171A0 (it) Procedimento per la preparazione della furosemide
FI895286A7 (fi) Fenyylioksipropanoliamineja, niiden valmistus ja terapeuttinen käyttö
DK424987D0 (da) Farmaceutisk praeparat til indgivelse gennem huden og fremgangsmaade til dets fremstilling
IT1282952B1 (it) Formulazioni farmaceutiche gastroresistenti contenenti colostro e uso del colostro per il trattamento della costipazione
ITRM930154A0 (it) Uso di terbinafina per il trattamento terapeutico della pneumocistosi.
ITTO920958A1 (it) Doccia per uso terapeutico.
IT8522559A0 (it) Coniugato della 9-(2-idrossietossimetil)guanina con albumina umana lattosaminata, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono.
DK701588D0 (da) N-hydroxy-5-phenyl-2-furancarboximidamider og anvendelse heraf til fremstilling af farmceutiske praeparater
ITMI920333A0 (it) Uso di sostanze parasimpaticomimetiche dirette per la terapia del dolore
ITRM940072A0 (it) Uso della ribonucleasi seminali per la terapia antimetastatica
DK13989A (da) Anvendelse af tnf og lt til fremstilling af laegemidler.
ITMI910328A1 (it) Uso della benzidamina per il trattamento della placca dentaria

Legal Events

Date Code Title Description
0001 Granted